✦ LIBER ✦

1124 ORAL Results of a randomized, double-blind phase II trial of ZD6474 versus gefitinib in patients with NSCLC

Book ID: 122746714
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 290 KB
Volume: 3
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(05)81419-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O-103 A comparison of the antitumour eff

O-103 A comparison of the antitumour efficacy of ZD6474 and gefitinib(Iressa™) in patients with NSCLC: Results of a randomized, double-blind Phase II study

✍ Natale, R.; Bodkin, D.; Govindan, R.; Sleckman, B.; Rizvi, N.; Capo, A.; Germonp 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 143 KB

O-100 ZD6474 plus docetaxel in patients

O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trial

✍ Herbst, R.; Johnson, B.; Rowbottom, J.; Fidias, P.; Lu, C.; Prager, D.; Roubec, 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 265 KB

Vandetanib Versus Gefitinib in Patients

Vandetanib Versus Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

✍ Natale, R. B.; Bodkin, D.; Govindan, R.; Sleckman, B. G.; Rizvi, N. A.; Capo, A. 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 210 KB

P-497 ZD6474 in combination with carbopl

P-497 ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II study

✍ Hevmach, J.; West, H.; Kerr, R.; Prager, D.; Sandler, A.; Herbst, R.; Stewart, D 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Monotherapy with the PCSK9 inhibitor ali

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

✍ Roth, Eli M.; Taskinen, Marja-Riitta; Ginsberg, Henry N.; Kastelein, John J.P.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 586 KB

3500 ORAL Preliminary results from a pha

3500 ORAL Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma

✍ G.K. Abou Alfa; P. Johnson; J. Knox; J. Lacava; T. Leung; A. Mori; M.A. Leberre; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 56 KB